Repositioning Candidate Details
| Candidate ID: | R0516 |
| Source ID: | DB01411 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Pranlukast |
| Synonyms: | Pranlukast |
| Molecular Formula: | C27H23N5O4 |
| SMILES: | O=C(NC1=C2OC(=CC(=O)C2=CC=C1)C1=NNN=N1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1 |
| Structure: |
|
| DrugBank Description: | Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens. |
| CAS Number: | 103177-37-3 |
| Molecular Weight: | 481.512 |
| DrugBank Indication: | Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. |
| DrugBank Pharmacology: | Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. |
| DrugBank MoA: | Pranlukast selectively antagonizes leukotriene D<sub>4</sub> (LTD<sub>4</sub>) at the cysteinyl leukotriene receptor, CysLT<sub>1</sub>, in the human airway. Pranlukast inhibits the actions of LTD<sub>4</sub> at the CysLT<sub>1</sub> receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus. |
| Targets: | Cysteinyl leukotriene receptor 1 antagonist; Tumor necrosis factor other/unknown; Interleukin-5 antagonist; Eosinophil cationic protein other/unknown; Nuclear factor NF-kappa-B p105 subunit other/unknown; Mucin-2 other/unknown |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|